Last updated on August 2016

Phase III Efficacy Safety and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP


Brief description of study

This is a Phase III, prospective, multicenter study with two study parts (epochs) to evaluate the efficacy, safety, and tolerability of HYQVIA/HyQvia (IGI, 10% with recombinant human hyaluronidase (rHuPH20) administered subcutaneously) for maintenance therapy to prevent relapse (Epoch 1) and GAMMAGARD LIQUID/KIOVIG (immunoglobulin G intravenous (IGIV) 10% administered intravenously) for the treatment of CIDP (Epoch 2). This study will enroll adult subjects with a confirmed diagnosis of CIDP and who have remained on a stable dosing regimen (monthly equivalent dose of 0.4 to 2.4 g/kg body weight (BW) with a dosing interval of 2 to 6 weeks) of IGIV therapy for at least 3 months prior to screening. In this double-blind, placebo-controlled phase of the study (Epoch 1), eligible subjects will be randomized in a 1:1 ratio to receive either HYQVIA/HyQvia or 0.25% albumin placebo solution with rHuPH20 every two, three, or four weeks in a double-blind fashion for a period of 6 months or until relapse. Subjects who relapse during Epoch 1 will enter Epoch 2 to receive IGIV treatment for a period of 6 months.

Clinical Study Identifier: NCT02549170

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Andras Nagy

Recherche Sepmus, Inc.
Greenfield Park, QC Canada
  Connect »

Andras Nagy

Fakultni nemocnice Ostrava
Ostrava - Poruba, Czech Republic
  Connect »

Andras Nagy

Fakultni nemocnice v Motole
Prague 5, Czech Republic
  Connect »

Andras Nagy

Vseobecna fakultni nemocnice v Praze
Praha 2, Czech Republic
  Connect »

Andras Nagy

Aarhus Universitetshospital
Aahus C, Denmark
  Connect »

Andras Nagy

Groupe Hospitalier Pellegrin - H pital Pellegrin
Bordeaux Cedex, France
  Connect »

Andras Nagy

IRCCS Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, Italy
  Connect »

Andras Nagy

Fondazione PTV - Policlinico Tor Vergata
Pozzilli, Italy
  Connect »

Andras Nagy

Azienda Ospedaliera Universitaria Policlinico G. Martino
Messina, Italy
  Connect »

Andras Nagy

Azienda Ospedaliero Universitaria Pisana
Pisa, Italy
  Connect »

Andras Nagy

Hospital Universitario Ramon y Cajal
Madrid, Spain
  Connect »

Andras Nagy

Hospital Universitario La Paz
Madrid, Spain
  Connect »

Andras Nagy

Hospital Universitari i Politecnic La Fe
Valencia, Spain
  Connect »

Andras Nagy

Sahlgrenska universitetssjukhuset
Goteborg, Sweden
  Connect »

Andras Nagy

King's College Hospital
London, United Kingdom
  Connect »

Andras Nagy

The Walton Centre
Liverpool, United Kingdom
  Connect »

Andras Nagy

Montreal Neurological Institute Clinical Research Unit
Montréal, QC Canada
  Connect »